Please login to the form below

Not currently logged in
Email:
Password:

CRISPR

This page shows the latest CRISPR news and features for those working in and with pharma, biotech and healthcare.

Sangamo’s first gene-editing trial doesn’t convince investors

Sangamo’s first gene-editing trial doesn’t convince investors

Sangamo has a lot riding on the outcome of this study, as it wants to position its ZFN platform as a rival to other gene-editing technologies, notably CRISPR/Cas9 and ... But companies developing other gene-editing technologies, such as CRISPR

Latest news

More from news
Approximately 3 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    CRISPR Therapeutics, one of the companies working with the exciting cutting-edge CRISPR/Cas9 gene editing technology, is looking to begin a phase I trial with Vertex on a candidate for

  • 30 women leaders in UK healthcare (part 3) 30 women leaders in UK healthcare (part 3)

    The greatest excitement is reserved for CRISPR-Cas9 gene editing, even though the technology is still in its infancy. ... CRISPR-Cas9 gene editing in.

  • Gene therapy Gene therapy

    From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines, oncolytic viruses and chemically modified mRNA.

  • Deal Watch March 2017 Deal Watch March 2017

    Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other

  • Winning the war against cancer Winning the war against cancer

    areas such as the gene-editing CRISPR technology.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Former GSK CEO joins Synthego’s advisory board Former GSK CEO joins Synthego’s advisory board

    Their recent rapid advances of the CRISPR field highlight their ability to execute on deep technology with a multidisciplinary, informatics-first approach.

  • Marc Becker joins CRISPR Therapeutics Marc Becker joins CRISPR Therapeutics

    Marc Becker joins CRISPR Therapeutics. He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing ... Becker said: “ I am excited to join the

  • CRISPR Therapeutics appoints Dr Tony Coles CRISPR Therapeutics appoints Dr Tony Coles

    CRISPR Therapeutics appoints Dr Tony Coles. He takes up a seat on the Swiss biopharma's board of directors. ... Swiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors.

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Creative Animodel

    Creative Animodel. Creative Animodel is an experienced bioscience CRO, which would like to help you accelerate the process through preclinical services including transgenic animals, animal models of disease, CRISPR genome editing

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics